Welcome to our dedicated page for Aurora Cannabis SEC filings (Ticker: ACB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Aurora Cannabis Inc. (ACB), a Canada-based global medical cannabis company listed on NASDAQ and the Toronto Stock Exchange. As a foreign private issuer, Aurora reports to the SEC primarily through Form 6-K current reports, which supply interim financial and operational information to investors.
Recent Form 6-K filings include condensed consolidated interim financial statements, management’s discussion and analysis for the three and six months ended September 30, 2025, and officer certifications. These documents outline Aurora’s segment results for global medical cannabis, consumer cannabis and plant propagation, along with adjusted gross margins, adjusted EBITDA, adjusted net income, working capital and details on cannabis inventory and biological assets.
Aurora also files 6-Ks that furnish material news releases, such as announcements of quarterly financial results, conference call schedules, facility investments and other corporate developments. Some of these 6-Ks are incorporated by reference into the company’s registration statements on Form F-10 and Form S-8, which support securities offerings and equity compensation plans.
On Stock Titan, each Aurora filing is paired with AI-powered summaries that explain the key points in clear language. Investors can quickly see how changes in medical cannabis revenue, consumer cannabis performance or plant propagation operations affect overall results, without reading every line of the underlying documents. Filings related to interim financial statements, management’s analysis and certifications are highlighted so users can focus on the disclosures that matter most for understanding ACB’s regulatory and financial reporting profile.
Aurora Cannabis Inc. (ACB) has furnished a routine Form 6-K with the U.S. SEC dated 19 June 2025. The filing’s sole purpose is to transmit Exhibit 99.1, identified as a "News release dated June 19, 2025." No financial statements, operational metrics, or transactional details accompany the submission. The document simply confirms that the Company continues to report under Form 40-F and is signed by CEO Miguel Martin. Because the actual news release is not included in the provided content, investors receive no new quantitative or strategic information from this 6-K alone.
Overview: Aurora Cannabis Inc. (ACB) filed a Form 6-K for the month of June 2025.
The filing is purely procedural and furnishes Exhibit 99.1—a news release dated 18 June 2025—without reproducing the release’s contents. No financial statements, earnings figures, or strategic transaction details are included. The cover page confirms that the company continues to file annual reports under Form 40-F and that Chief Executive Officer Miguel Martin signed the submission on 18 June 2025.
Investor takeaway: Because the underlying press release is not provided, this 6-K offers no quantitative data or substantive operational updates. It should therefore be viewed as routine compliance rather than a market-moving disclosure.
FAQ
What is the current stock price of Aurora Cannabis (ACB)?
What is the market cap of Aurora Cannabis (ACB)?
